Novo Nordisk has launched Awiqli, a new weekly basal insulin injection, in India. This innovative drug offers a once-weekly alternative to ...

The event celebrated the sector's growth, highlighting government commitment to a resilient, technology-driven MSME ecosystem. New initiati...

Vice President C. P. Radhakrishnan will inaugurate 'MSME Day 2026 – Udyami Bharat' in New Delhi, unveiling tools designed to simplify busin...

Shares of Natco Pharma and Eris Lifesciences climbed on Tuesday after announcing a partnership to commercialise Semaglutide in India. Natco...

Eris Lifesciences has partnered with Natco Pharma to introduce semaglutide in the Indian market a cutting-edge therapy for Type 2 diabetes ...

PM Modi stated that the production process of Eri Silk does not involve killing silkworms, making it an ethical and eco-friendly alternativ...

ITR filed by CA without password sharing: There is a way you can file ITR without sharing your e-filing ITR password with a chartered accou...

As part of the deal over 430 employees associated with the business are expected to transition to Eris, ensuring continuity for both employ...

Eris Lifesciences on Tuesday said it has acquired a 51 per cent stake in Swiss Parenterals for Rs 637.5 crore. Ahmedabad-based Swiss Parent...

Eris Lifesciences has announced that it has reached a definitive agreement to acquire the dermatology and nephrology branded formulations b...

Maharashtra is witnessing an uptick in cases following a period of decline, coinciding with the detection of new Covid Omicron subvariant E...

The deal for the portfolio that has an annual revenue base of 850 million rupees, will be financed through borrowings, and the transaction ...

The deal, through Eris' dermatology focused unit, is for the purchase of nine brands, including Onabet, Halobate, Sorvate, and Demelan for ...

The drug maker said the acquisition will be completed by way of a share purchase agreement as a result of which Oaknet will become a wholly...

The business of the joint venture will be kickstarted with the launch of human insulin in the fourth quarter of FY22.

The India branded generics business being divested by Strides had sales of Rs 181 core FY 2017, the statement said.

The acquisition is Eris’s fourth and the largest buyout in the last 18 months. With this, the company will be among the top ten companies i...